BBT002 is a first in human dual target antibody aimed at two inflammation proteins (IL 4Rα and IL 5) for allergic and eosinophilic disease; the half life came from a Phase 1 multiple ascending dose study in healthy volunteers, and the next test is a year end COPD readout.
Bambusa Therapeutics reported a roughly 29-day half-life for its experimental dual-target antibody BBT002 in healthy volunteers, a pharmacokinetic profile that, if it holds in patients, would let the company dose the drug as infrequently as every eight weeks. The half-life is the single most concrete number to emerge from the dataset, and it sets a concrete bar for comparison against existing biologics for Type 2 inflammation, the broad category of allergic and eosinophilic disease that includes asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps.
BBT002 is built to do something no approved drug does: block two separate inflammation signals at once, by binding both the IL-4 receptor alpha (a receptor on inflammatory cells that drives allergic and asthmatic responses) and IL-5 (a signaling protein that drives eosinophils, a type of white blood cell implicated in asthma, nasal polyps, and related diseases). The company is positioning the molecule as a "first-in-class" bispecific in this category, with the dual mechanism intended to cover a broader slice of Type 2 disease than single-target drugs can, per Bambusa's corporate site.
The new data come from the multiple-ascending-dose (MAD) portion of a randomized, blinded, placebo-controlled Phase 1 study in healthy volunteers, presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, June 12-15, 2026. The earlier single-ascending-dose (SAD) results were previously presented at the American Thoracic Society meeting in May. Bambusa's Chief Development Officer Thang Ho, Ph.D., described the MAD readout as showing "rapid, deep, and sustained" depletion of blood eosinophils, dose-dependent reductions in TARC (a chemokine tied to Th2 inflammation), and complete, sustained inhibition of pSTAT6, a downstream marker of IL-4/IL-13 pathway activity, all maintained for more than eight weeks after the last dose, with no apparent impact on safety or pharmacokinetics from anti-drug antibodies, according to the company's release. These are pharmacodynamic signals, not clinical outcomes, and the company has not yet reported patient data.
The half-life figure does the heaviest lifting in the company's pitch. Bambusa reported a BBT002 half-life of approximately 29.4 days at or above target exposure, a number consistent with the SAD data the company presented in May. In practical terms, a half-life in this range would let the company design a maintenance regimen of one shot every eight weeks or longer. The competitive question is not whether BBT002 hits two targets at once, but whether the half-life advantage translates into a meaningfully less burdensome schedule once the molecule is tested in patients with chronic disease.
Bambusa said BBT002 was well-tolerated across all SAD and MAD doses, with a low rate of anti-drug antibodies and no apparent effect on safety or pharmacokinetics. The company has not disclosed specific adverse event counts. The Phase 1 data are the only publicly available BBT002 results, and no peer-reviewed publication or independent readout is in hand.
The next test of the dosing-interval thesis is patient data. Bambusa is running two proof-of-concept (POC) studies: one in chronic obstructive pulmonary disease (COPD), with topline results expected by year-end 2026, and one in chronic rhinosinusitis with nasal polyps (CRSwNP), with topline anticipated in the first half of 2027. CRSwNP is a conventional indication for anti-eosinophil and anti-IL-4Rα therapies. COPD is a stretch goal, since the IL-4Rα and IL-5 pathways have not historically delivered strong efficacy in that population, and would be a much larger commercial prize if the drug works. Bambusa has framed its sister BBT001 atopic dermatitis program as a $40 billion-plus Type 2 dermatology market and the broader BBT002 opportunity as an $80 billion-plus Type 2 disorder market, citing its own market analysis on its corporate site.
Whether the half-life and dosing-interval advantage survive contact with real COPD patients is the question the year-end readout will need to answer.